Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/911,904	
	Filing Date	July 23, 2001	
	First Named Inventor	Spencer B. FARR	
	Group Art Unit	To Be Assigned	
	Examiner Name	To Be Assigned	
Total Number Of Pages In This Submission	10 + 35 REFS.	Attorney Docket No.	400742000200

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form plus copy for fee processing	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Form PTO-1449 plus copy (6 pages)
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> Request for Refund	2. Thirty-five (35) references
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	3. Return receipt postcard
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Morrison and Foerster, 755 Page Mill Road, Palo Alto, CA 94304
Signature	
Date	December 12, 2001

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on December 12, 2001.

Hazel M. Raskowitz

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



#3

PATENT
Docket No. 400742000200

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on December 12, 2001.

Hazel M. Raskowitz
Hazel M. Raskowitz

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Spencer B. FARR et al.

Serial No.: 09/911,904

Filing Date: July 23, 2001

For: CANINE TOXICITY GENES

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 400742000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 12, 2001

Respectfully submitted,

By: _____


Terri M. Shieh-Newton
Registration No. 47,081

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5649
Facsimile: (650) 494-0792

Form PTO-1449

Docket Number 400742000200

Application Number 09/911,904

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant


Spencer B. FARR et al.

Filing Date July 23, 2001

Group Art Unit To Be Assigned

Mailing Date December 12, 2001

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	09/05/2000	6,114,114	Brenner			
	2.	005/08/200	6,228,589	Seilhamer et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	3.	Ausubel, F. M. et al. eds. (1987). <u>Current Protocols in Molecular Biology</u> . John Wiley & Wiley & Sons, Inc. pp 1-9. (Table of Contents only).
	4.	Barnes, B. and Gordon, S. (1980). "Methods for Growth of Cultured Cells in Serum-Free Medium," <i>Anal. Biochem.</i> 102:255-270.
	5.	Coligan, J. E. et al, eds (1991). <u>Current Protocols in Immunology</u> . a Wiley & Sons, Inc. Publication. pp. 1-9. (Table of Contents only).
	6.	Diehn, M. et al. (1993). "Large-Scale Identification of Secreted and Membrane-Associated Gene Products Using DNA Microarrays," <i>Nat. Genet.</i> 25:58-62.
	7.	Feuerstein, G. Z., and Wang, X. (1997). "Use of Differential Display Reverse Transcription - Polymerase Chain Reaction for Discovery of Induced Adrenomedullin Gene Expression in Focal Stoke," <i>Can J. Physiol. Pharmacol.</i> 75:731-734.
	8.	Freshney, R. I. ed. (1987). <u>Animal Cell Culture, A Practical Approach</u> . IRL Press, Oxford Washington DC, pp vii-xii. (Table of Contents only).
	9.	Gait, M. J. ed. (1990). <u>Oligonucleotide Synthesis</u> . IRL Press, Oxford Washington DC, pp vii-xiii. (Table of Contents only).
	10.	Ham, R. G. and Wallace, W. L. (1979). "Media and Growth Requirements " <i>In Methods in Enzymology</i> Volume LVIII, Academic Press, Inc., pp. 44-93.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 400742000200	Application Number 09/911,904
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Spencer B. FARR et al.	
		Filing Date July 23, 2001	Group Art Unit To Be Assigned
		Mailing Date December 12, 2001	
			
	11.	Harlow, E. and Lane, D. (1988). <u>Antibodies: A Laboratory Manual</u> , Harlow, E. and Lane, D. eds., Cold Spring Harbor Laboratory, pp. iii-ix. (Table of Contents only).	
	12.	Hayes, A. W. ed. (2000). <u>Principals and Method in Toxicology</u> , Taylor & Frances, pp v-vii. (Table of Contents).	
	13.	Hayward, R. E. et al. (1993). "Shotgun DNA Microarrays and Stage-Specific Gene Expression in <i>Plasmodium Falciparum</i> Malaria," <i>Mol. Microbiol.</i> 35(1):6-14.	
	14.	Heuvel, John P. Vanden, ed. (1997). <u>PCR Protocols in Molecular Toxicology</u> . National Library of Medicine.	
	15.	Hough, C. D. et al. (2000). "Large-Scale Serial Analysis of Gene Expression Reveals Genes Differentially Expressed in Ovarian Canccer," <i>Cancer Res.</i> 60:6281-6287.	
	16.	Johannes, G. et al. (1999). "Identification of Eukaryotic mRNAs that Are Translated at Reduced Cap Binding Complex eIF4F Concentrations Using a cDNA Microarray," <i>Proc. Nat. Acad. Sci. USA</i> 96(23):13118-13123.	
	17.	Klein, P. E. et al. (2000). "A High-Throughput AFLP-based Method for Constructing Integrated Genetic and Physical Maps: Progress Toward a Sorghum Genome Map," <i>Genome Res.</i> 10:789-807.	
	18.	Liang, P. and Pardee, A. B. (1992). "Differential Display of Eukaryotic Messenger RNA by Means of the Olymerase Chain Reaction", <i>Science</i> 257:967-971.	
	19.	Liang, P. et al. (1993). "Distribution and Cloning of Eukaryotic mRNAs by Means of Differential Display: Refinements and Optimization," <i>Nucl. Acids. Res.</i> 21(14):3269-3275.	
	20.	Masseyeff, R. H. et al. eds. (1993). <u>Methods of Immunological Analysis</u> . Weinheim: VCH Verlags gesellschaft mbH, Vol. 1-3. (Table of Contents only).	
	21.	Miller, J. M. & Carlos, M. P. eds. (1987). <u>Gene Transfer Vectors for Mammalian Cells</u> . Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, pp. vii-ix. (Table of Contents only).	
	22.	Mullis, K. B. et al eds. (1994). <u>PCR: The Polymerase Chain Reaction</u> , Birkhäuser Boston, pp xv-xvii. (Table of Contents only).	
	23.	Nadeau, J. H. (1992). "Multilocus Markers for Mouse Genome Analysis: PCR Amplification Based on Single Primers of Arbitrary Nucleotide Sequence," <i>Genome</i> 3:55-64.	
	24.	Sambrook, J. et al (1989). <u>Molecular Cloning: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press, pp xi-xxxviii. (Table of Contents only)	
	25.	Scherf, U. et al. (2000). "A Gene Expression Database for the Molecular Pharmacology of Cancer," <i>Nat. Genet.</i> 24:236-44.	
	26.	Stahr, H. M. (1991). <u>Analytical Methods in Toxicology</u> . Wiley-Interscience Publication, John Wiley & Sons, Inc. pp. ix-xiii. (Table of Contents Only)	
	27.	Wang, X. and Feuerstein, G. Z. (1997). "The Use of mRNA Differential Display for Discovery of Novel Therapeutic Targets in Cardiovascular Disease," <i>Cardiovasc. Res.</i> 35(3):414-421.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449		Docket Number 400742000200	Application Number 09/911,904
INFORMATION DISCLOSURE CITATION MAN APPLICATION (Use several sheets if necessary) JAN 03 2002 PATENT & TRADEMARK OFFICE 8V		Applicant Spencer B. FARR et al.	
		Filing Date July 23, 2001	Group Art Unit To Be Assigned
		Mailing Date December 12, 2001	
	28.	Ward, D. M. & Blackwell, C. C. eds. <u>Handbook of Experimental Immunology in Four Volumes</u> , Volume 1-4. Blackwell Scientific Publication, fourth edition. (Table of Contents only).	
	29.	Welsh, J. et al. (1990). "Fingerprinting Genomes Using PCR with Arbitrary Primers," <i>Nucl. Acids Res.</i> 18(24):7213-7218.	
	30.	Welsh, J. et al. (1992). "Arbitrarily Primed PCR Fingerprinting of RNA," <i>Nucl. Acid Res.</i> 20:4965-4970.	
	31.	Wild, D. ed., (1994). <u>The Immunoassay Handbook</u> , Stockton Press NY, pp i-xix. (Table of Contents only).	
	32.	Williams, J. G. K. et al. (1990). "DNA Polymorphisms Amplified by Arbitrary Primers Are Useful as Genetic Markers," <i>Nucl. Acids. Res.</i> 18(22):6531-6535.	
	33.	Wilson, M. et al. (1999). "Exploring Drug-Induced Alterations in Gene Expression in <i>Mycobacterium Tuberculosis</i> by Microarray Hybridization," <i>Proc. Nat. Acad. Sci.</i> 96(22):12833-12838.	
	34.	Woodward, S. R. et al (1992). "Random Sequence Oligonucleotide Primers Detect polymorphic DNA products which Segregate in Inbred Strains of Mice," <i>Genome</i> 3:73-78.	
	35.	Ye, S. Q. et al. (2000). "MiniSage: Gene Expression Profiling Using Serial Analysis of Gene Expression from 1 µg Total RNA," <i>Anal. Biochem.</i> 287(1):144-152.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			